Novo-Nordisk ADR repsg 1 B Ord Shs NVO

Healthcare

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

NYSE:NVO - Post by User

Novo-Nordisk ADR repsg 1 B Ord Shs

Bullboard Posts

Post by jongguaon Oct 11, 2017 10:19am

322 Views

Post# 26798813

wits 1.0 not everywhere either

it is in 7 distinct places, with about 5-15 g/t averages for hundreds of square km's.

A dry hole for us is a dry hole. Doesn't kill wits 2.0 anymore than it did wits 1.0

Bullboard Posts

Rock Tech notches official permit for German lithium refinery